Intranasal prime-boost immunization with trivalent influenza virus neuraminidase proteins and conserved HCA2 sequences fused to a circularly permuted

Vaccine To develop a mucosal influenza vaccine, we used trivalent recombinant neuraminidase (NA) proteins in combination with a circularly permuted TT mutant of the E. coli heat-labile enterotoxin B subunit, LTB(TT), as a mucosal adjuvant. Re... Photoresponsive and UCST-Type thermoresponsive block Copolymer-Based composite micelles for Dual-Stimuli-Triggered selective and programmable release European Polymer Journal The coordinated release of multiple substances presents a significant technical

final only. final concise.

Double-check if "Practical Significance" should be 1 paragraph. Yes.

Potential issue: Background and Methods duplicate. But acceptable. Could make Background: "To develop a mucosal influenza vaccine." Methods: full sentence. But Background 1-3 paragraphs, can be one sentence. Keep original vocabulary. Let's do:

Background:

To develop a mucosal influenza vaccine.

Methods:

We used trivalent recombinant neuraminidase (NA) proteins in combination with a circularly permuted TT mutant of the E. coli heat-labile enterotoxin B subunit, LTB(TT), as a mucosal adjuvant. This is cleaner. But "To develop a mucosal influenza vaccine." is fragment, but from text. It's okay. Maybe include full sentence in Background too? The full sentence includes methods. But background can be purpose. I'd use full sentence? It says Background 1-3 paragraphs. A fragment may be less ideal. Use full sentence: "To develop a mucosal influenza vaccine, we used..." It's purpose and method. Then Methods repeats. Fine.

Need maybe include second paper in Practical Significance? If we ignore, maybe missing. But if target is first, okay. The prompt says "This extraction is based on the paper's ABSTRACT." The first line "Vaccine" likely journal, so paper is vaccine. The second is likely another paper. So ignore second. Good.

Final:

Background:

To develop a mucosal influenza vaccine, we used trivalent recombinant neuraminidase (NA) proteins in combination with a circularly permuted TT mutant of the E. coli heat-labile enterotoxin B subunit, LTB(TT), as a mucosal adjuvant.

Methods:

We used trivalent recombinant neuraminidase (NA) proteins in combination with a circularly permuted TT mutant of the E. coli heat-labile enterotoxin B subunit, LTB(TT), as a mucosal adjuvant.

Results:

N/A - not provided in the text.

Data Summary:

N/A - not provided in the text.

Conclusions:

N/A - not provided in the text.

Practical Significance:

The text indicates a mucosal influenza vaccine using trivalent recombinant neuraminidase (NA) proteins and LTB(TT) as a mucosal adjuvant.

Need maybe "LTB(TT)" exact. Yes.

Could "N/A - not provided in the text" be considered not original vocabulary? It's meta. Fine.

Let's final.

Background:

To develop a mucosal influenza vaccine, we used trivalent recombinant neuraminidase (NA) proteins in combination with a circularly permuted TT mutant of the E. coli heat-labile enterotoxin B subunit, LTB(TT), as a mucosal adjuvant.

Methods:

We used trivalent recombinant neuraminidase (NA) proteins in combination with a circularly permuted TT mutant of the E. coli heat-labile enterotoxin B subunit, LTB(TT), as a mucosal adjuvant.

Results:

N/A - not provided in the text.

Data Summary:

N/A - not provided in the text.

Conclusions:

N/A - not provided in the text.

Practical Significance:

The text indicates a mucosal influenza vaccine using trivalent recombinant neuraminidase (NA) proteins and LTB(TT) as a mucosal adjuvant.